Home
overview

SMi's 21st Annual Superbugs & Superdrugs Conference will take place on 18th - 19th March 2019

Inspiring the global commitment required to tackle multidrug-resistance among bacteria populations, as the global threat of antimicrobial resistance continues to grow.

This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.

Join us to learn about various strategies in place to support antimicrobial resistance research & development, evaluate the latest scientific advancements for tackling antimicrobial resistance and consider potential novel candidates and alternatives to anti-microbials.

The event will also focus on the strategies pharmaceutical companies use to assist the development of new therapeutics & drugs, how to obtain funding for new projects and address why there is a current lack of incentives for researchers working in antimicrobial resistance research and development.
 

By attending our 21st annual Superbugs & Superdrugs event, you will benefit from the knowledge delivered through range of thought-provoking presentations, by experts at the forefront of the field; receiving the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry – from research to commercial providers and regulatory bodies.

Analyse the current status of antimicrobial resistance with industry-led insight into current strategies to tackle AMR
Hear about novel immunotherapeutics to target Gram-negative bacterial infections
Learn about strategies to combat β-lactamases
Evaluate the development of precision antibiotics: agents designed to meet the demands of stewardship
Explore the role of plasmids in the evolution of antimicrobial resistance

  • Research and Development Directors
  • Chief Scientific Officers 
  • Chief Medical Officers
  • Heads of Global Antimicrobial Stewardship
  • Pharmaceutical Research & Development/ Drug Discovery Scientists

ABAC Therapeutics; Aberdeen University and Grampian University Hospitals; Achaogen Inc; Aelin Therapeutics NV; Alacrita LLP; Allecra Therapeutics SAS; AMR Centre; Antibiotic Research UK; Astellas Pharma Inc.; Autonomous University of Barcelona; BioPharm Insight; BioVersys AG; Centauri Therapeutics; Chemical Biology Ventures; ContraFect; Destiny Pharma; Drug Discovery Today; Drugs for Neglected Diseases initiative (DNDi); Eligo Bioscience; Emergent BioSolutions; Evotec; F2G Ltd; GARDP; Gladius Pharmaceuticals; GSK; HHS/ASPR/BARDA; Imperial College London; Infectious Diseases Hub; King Faisal Specilist Hospital & Research Center; King’s College London; King's College London; Laboratoire Biodim; LifeArc; Matoke Holdings; Melinta Therapeutics; Merck; MHRA; Microbiology Society; Micromyx LLC; Motif BioSciences; MSD; Mutabilis; mycoBiologics @ University of Aberdeen; Neem Biotech; Nemesis bioscience ; Novo AS; Office Of Health Economics; Oppilotech; Pew charitable trusts; Phico Therapeutics; PSI CRO AG; SCYNEXIS Inc; Summit Therapeutics; Sygnature Discovery; TranScrip Partners; University Of Birmingham; University of North Texas Health Science Center; UNTHSC, PreClinical Services; VAST Bioscience Pty Ltd; Virbac; Walter Reed Army Institute of Research; Wellcome Uk; West Way Health;

Conference programme

8:30 Registration & Coffee

9:00 Co-chairmen's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

Lloyd Czaplewski

Lloyd Czaplewski, Director, Chemical Biology Ventures

9:15 Anti-infective research: funding, filing and finance

John  Rex

John Rex, Chief Medical Officer , F2G Ltd

• Update on funding initiatives
• Recent changes in the regulatory landscape
• Payer models: evolving global discussions
 

9:55 Strategies to combat ß-lactamases

Christopher Schofield

Christopher Schofield, Head of Organic Chemistry, Oxford University
View Bio

• The β-lactams remain the most important antibiotics
• The most important mechanism of resistance to them involves serine- and metallo-β-lactamase mediated hydrolysis
• Successes and challenges in inhibiting β-lactamases will be described, highlighting the need for investment in technically demanding chemistry


 

10:35 Morning Coffee

11:05 A unique combination antibiotic therapy at Helperby

Anthony Coates

Anthony Coates, Chief Scientific Officer, St George's, University of London
View Bio

• The combination of azidothymidine (AZT) and low-dose colistin shows synergistic antibiotic activity against carbapenem and colistin-resistant Enterobacteriaceae (CRE) infections.
• This was shown to be active against all three of the WHO Critical Priority Carbapenem resistant bacterial pathogens
• Combining antimicrobial resistance breakers such as azidothymidine with existing antibiotics has the potential to reach the market with a new class of effective antibiotic therapy in 3 to 5 years
 

11:45 Immunotherapeutics targeting Pseudomonas aeruginosa acute and persistent infections

Antonio DiGiandomenico

Antonio DiGiandomenico, Principal Scientist, MedImmune Oncology Inc.

• Novel anti-Pseudomonal mAbs and insights into their mechanisms of action
• Activity in multiple animal models - in both prophylaxis and treatment indications
• Measuring activity against biofilms
• Antibiotic treatment synergy
 

12:25 Networking Lunch

13:25 Next generation antimicrobial therapies for lethal drug resistant bacterial infections

Chandrabali Ghose

Chandrabali Ghose, CEO, Bioharmony Therapeutics
View Bio

• Insight into the development of a pipeline of lysins for infections caused by multidrug-resistant Gram-Negative bacteria
• Demonstration of effectiveness in Gram-Negative bacteria such as Acinetobacter baumannii, Klebsiella pneumoniae, E.coli and Pseudomonas aeruginosa.
• Extreme importance due to high unmet medical need and the declining number of effective antibiotics
 

14:05 The development of ME1111 at Meiji Seika

Kazunori Maebashi

Kazunori Maebashi, Senior Project Manager, Meiji Seika Pharma Co. Ltd.
View Bio

• A new class of 2-aminoamidazole molecules that inhibit bacterial protection mechanisms
• Disperse and inhibit biofilm formation
• Lowers effective dose of antibiotic
• Mitigates onset of resistance
 

14:45 Afternoon Tea

15:15 Activity of Ibrexafungerp in murine models of pneumocystis pneumonia

Stephen Barat

Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
View Bio

• Background on pneumocystis pneumonia.
• Introduction to Ibrexafungerp, the first example of the fungerps, a new class of anti-fungal agents.
• Evaluations in prophylaxis and treatment murine models of pneumocystis pneumonia.
• Potential clinical applications.
 

15:55 Developing new therapies for fungal infection

David Cook

David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd
View Bio

• Fungal disease is a major public health issue that gets very little attention. Dermal fungal infections are amongst the most common but often considered “trivial”. In contrast, serious fungal infections, particularly in immune-compromised patients, have extremely high mortality rates and limited treatment options.
• Exploring efforts in the development of new treatments for common fungal infections
• Needs and challenges in developing new anti-fungals
 

16:35 Co-chairmen’s Closing Remarks and Close of Day One

Lloyd Czaplewski

Lloyd Czaplewski, Director, Chemical Biology Ventures

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

8:30 Registration & Coffee

9:00 Co-chairmen's Opening Remarks

Lloyd Czaplewski

Lloyd Czaplewski, Director, Chemical Biology Ventures

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

9:10 Regulatory considerations for the registration of new antibacterial agents

Mair Powell

Mair Powell, Senior Medical Officer, HPRA
View Bio

• Ensuring that candidate antibacterial agents with potential to address an unmet need are evaluated in line with regulatory guidance
• Options for clinical development programmes
• Importance of the pharmacokinetic-pharmacodynamic relationship
• Update on recent guidance and planned revisions to EMA guidance
 

9:50 Wellcome Trust: funding opportunities for anti-infective research

Timothy Jinks

Timothy Jinks, Senior Business Analyst, Wellcome Trust

• Introducing Wellcome Trust Innovations - What is our mission?
• How we are seeking innovative therapeutics and diagnostics to transform the treatment of infectious diseases
• Examples of success
• The selection process and a view of the investment selection criteria
 

10:30 Morning Coffee

11:00 Novel immunotherapeutics to target Gram-negative bacterial infections

Chris Pickford

Chris Pickford, Head of Drug Discovery, Centauri Therapeutics
View Bio

• A summary of novel approaches to target Gram-negative bacterial infections
• Emerging immunotherapeutics
• The opportunities and challenges involved in pre-clinical development of novel immunotherapies
• Specific targeting of Gram-negative bacteria with Centauri Therapeutics AlphamersTM 
 

11:40 The role of plasmids in the evolution of antimicrobial resistance

Laura Piddock

Laura Piddock, Professor of Microbiology, University of Birmingham

• How have plasmids impacted the spread of antimicrobial resistance?
• What impact do plasmids have on the host bacteria?
• What novel strategies to reduce the burden of resistance plasmids are currently being explored?
 

12:20 Networking Lunch

13:20 The development of precision antibiotics: agents designed to meet the demands of stewardship

David Roblin

David Roblin, President of R&D, Chief Operating Officer and Chief Medical Officer, Summit Theraputics
View Bio

Summit’s development strategy exemplifies good antibiotic stewardship and I will focus on two programmes from our antibiotic pipeline:

• Ridinilazole is a narrow spectrum, new mechanism of action antibiotic for the treatment of C. difficile infection and the reduction of disease recurrence.  Ridinilazole’s narrow spectrum of activity is important: it both treats the infection whilst preserving the microbiome from further perturbation and thus reducing recurrences. Summit’s Phase 3 development programme is designed to show ridinilazole has superiority over vancomycin and support its use as a new first line therapy.

• SMT-571 a novel first-in-class oral antibiotic with activity effective against the Gram-negative bacterial pathogen, Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection gonorrhoea.  SMT-571 has the potential to satisfy the Target Product Profile (TPP), recommended by the World Health Organization (WHO) and Drugs for Neglected Disease initiative (DNDi) for an oral agent to treat multi-drug resistant gonorrhoea.
 

14:00 Novel methods for treating infections – Inducing antimicrobial peptides

Eirikur Steingrimsson

Eirikur Steingrimsson, Co-founder, Akthelia Pharmaceuticals
View Bio

• Akthelia has identified several small molecules that induce the production of AMPs in cells, thus leading to elimination of bacteria. 
• Several peptides are induced thereby reducing the risk of the bacteria acquiring resistance against a single peptide. 
• Thus, Akthelia’s solution treats infections by inducing the body’s own antibiotic arsenal. This mechanism has been shown to be active against most microbial pathogens, including resistant microorganisms.
• Akthelia´s actives facilitate anti-infective stewardship as they reduce the usage of classical antibiotics with minimal risk of the development of resistance.
• Importantly, they should leave the microbiota intact.
 

14:40 Afternoon Tea

15:10 Pharmacodynamics to accelerate antimicrobial drug development for AMR

William  Hope

William Hope , Professor of Therapeutics and Infectious Diseases, University Of Liverpool
View Bio

• Identification of the drug's antimicrobial pharmacodynamic effects (eg, rate and extent of bactericidal action and post-antibiotic effect)
• It provides a more rational basis for determination of optimal dosing regimens in terms of the dose and the dosing interval
• Why it is preferred compared to minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) determined in vitro
 

15:50 Optimized arylomycins represent a new class of Gram-negative antibiotics

Michael Koehler

Michael Koehler, Senior Scientist, Genentech

• Chemical optimization of the arylomycins-a class of natural products with weak activity and limited spectrum-to obtain  G0775, a molecule with potent, broad-spectrum activity against Gram-negative bacteria
• G0775 inhibits the essential bacterial type I signal peptidase, a new antibiotic target, through an unprecedented molecular mechanism
• It circumvents existing antibiotic resistance mechanisms and retains activity against contemporary multidrug-resistant Gram-negative clinical isolates in vitro and in several in vivo infection models
• Optimized arylomycin analogues such as G0775 could translate into new therapies to address the growing threat of multidrug-resistant Gram-negative infections

16:30 Co-chairmen’s Closing Remarks and Close of Day Two

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

Lloyd Czaplewski

Lloyd Czaplewski, Director, Chemical Biology Ventures

+

FEATURED SPEAKERS

Antonio DiGiandomenico

Antonio DiGiandomenico

Principal Scientist, MedImmune Oncology Inc.
Chandrabali Ghose

Chandrabali Ghose

CEO, Bioharmony Therapeutics
Chris Pickford

Chris Pickford

Head of Drug Discovery, Centauri Therapeutics
Christopher Schofield

Christopher Schofield

Head of Organic Chemistry, Oxford University
David Cook

David Cook

Chief Scientific Officer, Blueberry Therapeutics Ltd
David Roblin

David Roblin

President of R&D, Chief Operating Officer and Chief Medical Officer, Summit Theraputics
John  Rex

John Rex

Chief Medical Officer , F2G Ltd
Kazunori Maebashi

Kazunori Maebashi

Senior Project Manager, Meiji Seika Pharma Co. Ltd.
Laura Piddock

Laura Piddock

Professor of Microbiology, University of Birmingham
Lloyd Czaplewski

Lloyd Czaplewski

Director, Chemical Biology Ventures
Richard Bax

Richard Bax

Senior Partner, TranScrip Partners
William  Hope

William Hope

Professor of Therapeutics and Infectious Diseases, University Of Liverpool

Anthony Coates

Chief Scientific Officer, St George's, University of London
Anthony Coates

Professor Anthony Coates founded Helperby Therapeutics in 2002.

With his colleague Dr Yanmin Hu he invented and patented a new way of discovering combinations of antibiotics which kill highly resistant bacteria. The Company is now in clinical trials with potential new combination treatments for multi-drug resistant bacterial infections.

Sir Anthony is the Professor of Medical Microbiology at St George’s, University of London, leads research teams, is author of over 150 publications, and is recipient of national & international grants from the European Commission and industry.
 

Antonio DiGiandomenico

Principal Scientist, MedImmune Oncology Inc.
Antonio DiGiandomenico

Chandrabali Ghose

CEO, Bioharmony Therapeutics
Chandrabali Ghose

Chandrabali Ghose is the founder and CEO of Bioharmony Therapeutics, an early-stage biotech startup specializing in the development of novel antimicrobials to combat drug-resistant bacterial infections. Chandra spent 8 years at the Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University. Prior to that, Chandra was a postdoctoral fellow at Harvard Medical School. Chandra earned her PhD from New York University School of Medicine and her bachelor’s degree from Saint Louis University. She has published high-impact peer-reviewed articles and book chapters in the field of infectious diseases and has received many awards for her scientific and entrepreneurial contributions.

Chris Pickford

Head of Drug Discovery, Centauri Therapeutics
Chris Pickford

Chris is currently the Head of Drug Discovery at Centauri Therapeutics. He leads the scientific team to deliver drug candidates into the clinic, responsible for the pre-clinical labs at Discovery Park, Sandwich, UK. Before joining Centauri Therapeutics, Chris was a Research Director at Agalimmune, an immuno-oncology biotech and a project leader for Salvensis, a neglected diseases drug discovery company. In addition, Chris worked for 12 years as part of Pfizer’s Research and Development organization, leading infectious diseases projects from new target identification to first-in-human trials. Chris studied for a biochemistry degree at the University of Birmingham and obtained a PhD from the National Institute of Medical Research, London

Christopher Schofield

Head of Organic Chemistry, Oxford University
Christopher Schofield

Chris Schofield studied for a degree in chemistry at the University of Manchester (1979-1982). In 1982 he moved to Oxford for DPhil studies with Jack Baldwin on the synthesis and biosynthesis of antibiotics. In 1985 he became a Departmental Demonstrator in the Dyson Perrins Laboratory, and in 1990 Lecturer in Chemistry and Fellow of Hertford College. In 1998 he became Professor of Chemistry, and in 2011 was appointed Head of Organic Chemistry. He is a Fellow of the Royal Society.

His research group works at the interface of chemistry, biology and medicine. His work has opened up new fields in antibiotic research, oxygen sensing and gene regulation in organisms ranging from bacteria to plants and animals. His work has identified new opportunities for medicinal intervention that are being pursued by numerous academic and commercial laboratories.
 

David Cook

Chief Scientific Officer, Blueberry Therapeutics Ltd
David Cook

David has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London and three years of post-doctoral experience. David has worked in the pharmaceutical industry for almost 20 years. He worked in big pharma at AstraZeneca for more than 17 years in a wide variety of R&D roles both in the UK and the US. Whilst at AstraZeneca he was heavily involved in developing the use of informatics and systems biology to support the development of new medicines. David joined Blueberry Therapeutics as Chief Scientific Officer at the start of 2014. In this role, he is responsible for leading the research activities of the business which are focused on developing new treatments for common dermatological diseases. The first of these treatments is now in clinical testing.

David Roblin

President of R&D, Chief Operating Officer and Chief Medical Officer, Summit Theraputics
David Roblin

David is an experienced scientist and physician, with a distinguished career in the pharmaceutical industry. He and his units have brought many medicines in several therapy areas through R&D to successful commercialisation; including in anti-infectives azithromycin, ciprofloxacin, moxifloxacin, voriconazole and selzentry.
He is currently President of R&D at Summit Therapeutics plc, an international clinical-stage company listed on AIM and NASDAQ developing new mechanism antibiotics. David is also a non-executive director of Sosei PLC and sits on a variety of committees at Wellcome, on the UK Biomedical Catalyst Fund and the LEO Foundation prize committee.
He has previously served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London (2014 – 2017). Prior to this, he was Head of Research and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999.
David has a degree in biochemistry from University of London and qualified in Medicine from St George’s Hospital, London. He is a Fellow of the Royal College of Physicians, Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Academy of Medical Sciences. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s.

Eirikur Steingrimsson

Co-founder, Akthelia Pharmaceuticals
Eirikur Steingrimsson

Eirikur Steingrimsson is a founder of Akthelia and professor of Molecular Biology in the Faculty of Medicine at the University of Iceland and is an expert in gene regulation. He has over 20 years of experience in this area and has published his work in leading international journals. He is an EMBO member. During the years 2003-2005 he served as the CSO of Iceland Genomics Corporation, now a component of Decode Genetics.

John Rex

Chief Medical Officer , F2G Ltd
John  Rex

Kazunori Maebashi

Senior Project Manager, Meiji Seika Pharma Co. Ltd.
Kazunori Maebashi

Dr. Kazunori Maebashi has been a Senior Project Manager at Meiji Seika Pharma Co., Ltd., Japan since 2011. He became a researcher at Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd. in 2000. During 1986-2000, he worked for Central Research Laboratories at SSP Co., Ltd., Japan. His experiences range from drug discovery to clinical phases of antibacterial and antifungal agents. He contributed to research and development of drugs such as tebipenem pivoxil (oral carbapenem), ME1071 (metallo-β-lactamase inhibitor), TS2037 (aminoglycoside) and neticonazole (antifungal imidazole). Recently, he has promoted ME1111 program, topical antifungal drug development for onychomycosis, as a project manager.

Laura Piddock

Professor of Microbiology, University of Birmingham
Laura Piddock

Lloyd Czaplewski

Director, Chemical Biology Ventures
Lloyd Czaplewski

Mair Powell

Senior Medical Officer, HPRA
Mair Powell

Dr. Powell underwent post-graduate training in clinical microbiology and infectious diseases. After 11 years in hospital medicine she worked for two global pharmaceutical companies in the US and then returned to the UK to work for the MHRA. She is a member of the EMA’s Infectious Disease Working Party and was its chair for 6 years. She has been closely involved in all guideline development for anti-infective agents for 20 years. She is currently the chair of the EMA’s Vaccine Working Party and a member of the Scientific Advice Working Party.

Michael Koehler

Senior Scientist, Genentech
Michael Koehler

Richard Bax

Senior Partner, TranScrip Partners
Richard Bax

Stephen Barat

Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
Stephen Barat

Stephen A. Barat, PhD is Vice-President of Research and Early Clinical Development at Scynexis, a NJ-based biotechnology company focused on the development of novel treatments for serious and life-threatening infections. Prior to joining Scynexis, Dr. Barat held a series of positions of increasing responsibility with Allergan, Forest Laboratories and Schering-Plough. He has more than 20 years of experience in global drug development and registration, and is an internationally-recognized speaker on the subject of drug development and CMC-related safety assessment issues. Dr. Barat is a member of the PQRI PODP working group for leachables and extractables and the USP Expert Panel for Biocompatibility of Packaging Materials.

Timothy Jinks

Senior Business Analyst, Wellcome Trust
Timothy Jinks

William Hope

Professor of Therapeutics and Infectious Diseases, University Of Liverpool
William  Hope

William Hope (BMBS, FRACP, FRCPA, PhD), is Professor of Therapeutics and Infectious Diseases at the University of Liverpool in the UK. Professor Hope is a Fellow of the Royal Australasian College of Physicians and a Fellow of the Royal College of Pathologists of Australasia. Professor Hope qualified in Medicine in 1991, before undertaking specialist training in infectious diseases and clinical microbiology. He completed his PhD in antimicrobial pharmacology in 2006, while undertaking fellowships at the University of Manchester, UK, and the National Institutes of Health, Bethesda, USA. He was an NIHR Clinician Scientist and this award focused on individualised antimicrobial therapy. Professor Hope leads the newly formed Centre for Antimicrobial Pharmacodynamics, which provides the pharmacodynamic packages for new antibiotics. Areas of special interest and research are antimicrobial pharmacokinetics and pharmacodynamics, antimicrobial drug development and individualisation of antimicrobial therapy. He is a Fellow of the American Academy of Microbiology and European Society of Clinical Microbiology and Infectious Diseases.

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out